According to the law firm press release, the lawsuit alleges defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that (1) Lion Biotechnologies, through its former CEO, engaged in a scheme to mislead investors by commissioning over 10 internet publications and 20 widely distributed emails promoting Lion Biotechnologies to potential investors that purported to be independent from the company when, in fact, they were paid promotions; (2) the former CEO engaged a notorious stock promotion firm to pay writers to publish articles about Lion Biotechnologies on investment websites as well as to coordinate the distribution of articles to thousands of electronic mailboxes; (3) the former CEO actively participated in the promotional work for Lion Biotechnologies and understood that the promotion firm was using writers who would not disclose that Lion Biotechnologies was indirectly compensating them for their publications; and (4) as a result, defendants\\\\' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
Lion Biotechnologies, Inc. Securities Litigation
May 24, 2017 | Lion Biotechnologies, Inc. NASDAQ: LBIO | Case Status: Settled
If you purchased a significant amount of shares of Lion Biotechnologies, Inc. (NASDAQ: LBIO), you have certain options. Investors should register for updates.
Sign up for free to create a personalized portfolio with tracking and e-mail alerts for Lion Biotechnologies, Inc.
First Identified Complaint
Leonard Desilvio, et al. v. Lion Biotechnologies, Inc., et al.
First Identified Complaint Filings
|#||Document Title||Filing Date|
|1||Class Action Complaint for Violation of the Federal Securities Laws||April 14th, 2017|